NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McAlister FA, Ezekowitz J, Dryden DM, et al. Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jun. (Evidence Reports/Technology Assessments, No. 152.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction

Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction.

Show details

References and Included Studies

1.
Leclercq C, Cazeau S, Le Breton H. et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol. 1998;32(7):1825–31. [PubMed: 9857858]
2.
Nelson GS, Berger RD, Fetics BJ. et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000;102(25):3053–9. [PubMed: 11120694]
3.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. [PubMed: 12111919]
4.
Abraham WT, Fisher WG, Smith AL. et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53. [PubMed: 12063368]
5.
Cazeau S, Leclercq C, Lavergne T. et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay (MUSTIC SR) N Engl J Med. 2001;344(12):873–80. [PubMed: 11259720]
6.
Young JB, Abraham WT, Smith AL. et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685–94. [PubMed: 12771115]
7.
Leclercq C, Walker S, Linde C. et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation (MUSTIC AF) Eur Heart J. 2002a;23(22):1780–7. [PubMed: 12419298]
8.
Auricchio A, Stellbrink C, Sack S. et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay (PATH CHF Trial) J Am Coll Cardiol. 2002a;39(12):2026–33. [PubMed: 12084604]
9.
Higgins SL, Hummel JD, Niazi IK. et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42(8):1454–9. [PubMed: 14563591]
10.
Leclercq C, Cazeau S, Lellouche D. Upgrading from right ventricular pacing to biventricular pacing in previously paced patients with advanced heart failure: a randomized controlled study (RD-CHF). European Society of Cardiology Congress; Aug 30–Sep 3; Vienna, Austria. 2003.
11.
Bristow MR, Saxon LA, Boehmer J. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50. [PubMed: 15152059]
12.
Auricchio A, Stellbrink C, Butter C. et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42(12):2109–16. [PubMed: 14680736]
13.
Kindermann M, Hennen B, Jung J. et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE) J Am Coll Cardiol. 2006;47(10):1927–37. [PubMed: 16697307]
14.
Abraham WT, Young JB, Leon AR. et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110(18):2864–8. [PubMed: 15505095]
15.
Cleland JGF, Daubert JC, Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49. [PubMed: 15753115]
16.
U.S. Food and Drug Administration. St. Jude Medical Frontier™ model 5508L and Frontier™ II model 5586 cardiac resynchronization therapy pacemakers (CRT-P) supported on the model 3510 programmer platforms with the model 3307, v4.8m programmer software: part 2 - summary of safety and effectiveness [VecTOR][Web Page]. 2005; Available at http://www​.fda.gov/cdrh​/pdf3/p030035s003b.pdf. (Accessed 25 September 2006).
17.
U.S. Food and Drug Administration. St. Jude Medical® Epic™ HF System including the Epic™ HF Model V-338 cardiac resynchronization therapy defibrillator, the Aescula™ LV model 1055K lead, the QuickSite™ LV model 1056K lead, and the model 3307, v4.5m programmer software: part 2 - summary of safety and effectiveness [RHYTHM ICD][Web Page]. 2005; Available at http://www​.fda.gov/cdrh/pdf3/P030054b​.pdf. (Accessed 25 September 2006).
18.
Achilli A, Sassara M, Ficili S. et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and "narrow" QRS. J Am Coll Cardiol. 2003;42(12):2117–24. [PubMed: 14680737]
19.
Adamson PB, Smith AL, Abraham WT. et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation. 2004;110(16):2389–94. [PubMed: 15313946]
20.
Albertsen AE, Nielsen JC, Pedersen AK. et al. Left ventricular lead performance in cardiac resynchronization therapy: impact of lead localization and complications. Pacing Clin Electrophysiol. 2005;28(6):483–8. [PubMed: 15955178]
21.
Alonso C, Leclercq C, Victor F. et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. Am J Cardiol. 1999;84(12):1417–21. [PubMed: 10606115]
22.
Ammann P, Kiencke S, Schaer B. et al. Cardiac resynchronization in severe heart failure and left bundle branch block: a single center experience. Swiss Med Wkly. 2004;134(1920):277–82. [PubMed: 15243848]
23.
Ansalone G, Giannantoni P, Ricci R. et al. Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. J Am Coll Cardiol. 2002;39(3):489–99. [PubMed: 11823088]
24.
Aranda JM Jr, Woo GW, Conti JB. et al. Use of cardiac resynchronization therapy to optimize beta-blocker therapy in patients with heart failure and prolonged QRS duration. Am J Cardiol. 2005;95(7):889–91. [PubMed: 15781026]
25.
Auricchio A, Kloss M, Trautmann SI. et al. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Am J Cardiol. 2002b;89(2):198–203. [PubMed: 11792342]
26.
Azizi M, Castel MA, Behrens S. et al. Experience with coronary sinus lead implantations for cardiac resynchronization therapy in 244 patients. Herzschrittmacherther Elektrophysiol. 2006;17(1):13–8. [PubMed: 16547655]
27.
Baker CM, Christopher TJ, Smith PF. et al. Addition of a left ventricular lead to conventional pacing systems in patients with congestive heart failure: feasibility, safety, and early results in 60 consecutive patients. Pacing Clin Electrophysiol. 2002;25(8):1166–71. [PubMed: 12358165]
28.
Bax JJ, Marwick TH, Molhoek SG. et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. Am J Cardiol. 2003;92(10):1238–40. [PubMed: 14609610]
29.
Bax JJ, Bleeker GB, Marwick TH. et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2004;44(9):1834–40. [PubMed: 15519016]
30.
Bleeker GB, Schalij MJ, Molhoek SG. et al. Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus > or =70 years of age. Am J Cardiol. 2005a;96(3):420–2. [PubMed: 16054473]
31.
Bleeker GB, Schalij MJ, Nihoyannopoulos P. et al. Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol. 2005b;46(12):2264–9. [PubMed: 16360056]
32.
Bleeker GB, Schalij MJ, Holman ER. et al. Cardiac resynchronization therapy in patients with systolic left ventricular dysfunction and symptoms of mild heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2006;98(2):230–5. [PubMed: 16828599]
33.
Bocchiardo M, Padeletti L, Gasparini M. et al. Biventricular pacing in patients candidate to an ICD. Eur Heart J. 2000;2(Suppl J):J36–J40.
34.
Bonanno C, Ometto R, Pasinato S. et al. Effects of cardiac resynchronization therapy on disease progression in patients with congestive heart failure. Ital Heart J. 2004;5(5):364–70. [PubMed: 15185900]
35.
Bordachar P, Lafitte S, Reuter S. et al. Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing. J Am Coll Cardiol. 2004;44(11):2157–65. [PubMed: 15582313]
36.
Boriani G, Muller CP, Seidl KH. et al. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study. Am Heart J. 2006a;151(5):1050–8. [PubMed: 16644335]
37.
Boriani G, Gasparini M, Lunati M. et al. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. Am Heart J. 2006b;152(3):527. e1–11. [PubMed: 16923425]
38.
Boriani G, Regoli F, Saporito D. et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides. 2006c;27(7):1776–86. [PubMed: 16621149]
39.
Braun MU, Rauwolf T, Zerm T. et al. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart. 2005;91(5):601–5. [PMC free article: PMC1768894] [PubMed: 15831642]
40.
Braunschweig F, Mortensen PT, Gras D. et al. Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices. Am J Cardiol. 2005;95(9):1104–7. [PubMed: 15842984]
41.
Cazeau S, Jauvert G, Alonso C. et al. Echographic modelling of cardiac asynchronism: prospective evaluation before and after multisite stimulation [in French] Arch Mal Coeur Vaiss. 2003;96(6):659–64. [PubMed: 12868348]
42.
Chalil S, Yousef ZR, Muyhaldeen SA. et al. Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchronization therapy. J Am Coll Cardiol. 2006;47(12):2486–92. [PubMed: 16781378]
43.
Chan KL, Tang AS, Achilli A. et al. Functional and echocardiographic improvement following multisite biventricular pacing for congestive heart failure. Can J Cardiol. 2003;19(4):387–90. [PubMed: 12704484]
44.
Cowburn PJ, Patel H, Pipes RR. et al. Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity. Eur J Heart Fail. 2005;17(5):899–903. [PubMed: 15919239]
45.
Da Costa A, Thevenin J, Roche F. et al. Prospective validation of stress echocardiography as an identifier of cardiac resynchronization therapy responders. Heart Rhythm. 2006;3(4):406–13. [PubMed: 16567286]
46.
Daubert JC, Ritter P, Le Breton H. et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol. 1998;21(1 Pt 2):239–45. [PubMed: 9474680]
47.
Davis DR, Krahn AD, Tang AS. et al. Long-term outcome of cardiac resynchronization therapy in patients with severe congestive heart failure. Can J Cardiol. 2005;21(5):413–7. [PubMed: 15861258]
48.
de Sisti A, Toussaint JF, Lavergne T. et al. Determinants of mortality in patients undergoing cardiac resynchronization therapy: baseline clinical, echocardiographic, and angioscintigraphic evaluation prior to resynchronization. Pacing Clin Electrophysiol. 2005;28(12):1260–70. [PubMed: 16403157]
49.
Diaz-Infante E, Mont L, Leal J. et al. Predictors of lack of response to resynchronization therapy. Am J Cardiol. 2005;95(12):1436–40. [PubMed: 15950566]
50.
Dixon LJ, Murtagh JG, Richardson SG. et al. Reduction in hospitalization rates following cardiac resynchronisation therapy in cardiac failure: experience from a single centre. Europace. 2004;6(6):586–9. [PubMed: 15519262]
51.
Duncan AM, Lim E, Clague J. et al. Comparison of segmental and global markers of dyssynchrony in predicting clinical response to cardiac resynchronization. Eur Heart J. 2006;27(20):2426–32. [PubMed: 16882676]
52.
Ellery S, Paul V, Prenner G. et al. A new endocardial “over-the-wire” or stylet-driven left ventricular lead: first clinical experience. Pacing Clin Electrophysiol. 2005;28(Suppl 1):S31–S35. [PubMed: 15683519]
53.
Ermis C, Lurie KG, Zhu AX. et al. Biventricular implantable cardioverter defibrillators improve survival compared with biventricular pacing alone in patients with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2004;15(8):862–6. [PubMed: 15333075]
54.
Fung JW, Yu CM, Chan JY. et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol. 2005;96(5):728–31. [PubMed: 16125504]
55.
Gaita F, Bocchiardo M, Porciani MC. et al. Should stimulation therapy for congestive heart failure be combined with defibrillation backup? Am J Cardiol. 2000;86(9A):165K–58K. [PubMed: 11084118]
56.
Galvao SS, Barcellos CM, Vasconcelos JT. et al. Ventricular resynchronization through biventricular cardiac pacing for the treatment of refractory heart failure in dilated cardiomyopathy. Arq Bras Cardiol. 2002;78(1):39–50. [PubMed: 11826346]
57.
Gasparini M, Mantica M, Galimberti P. et al. Beneficial effects of biventricular pacing in patients with a “narrow” QRS. Pacing Clin Electrophysiol. 2003a;26(1 Pt 2):169–74. [PubMed: 12687806]
58.
Gras D, Leclercq C, Tang AS. et al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur J Heart Fail. 2002;4(3):311–20. [PubMed: 12034157]
59.
Hernandez Madrid A, Miguelanez Diaz M, Escobar Cervantes C. et al. Usefulness of brain natriuretic peptide to evaluate patients with heart failure treated with cardiac resynchronization [in Spanish] Rev Esp Cardiol. 2004;57(4):299–305. [PubMed: 15104983]
60.
Hua W, Niu HX, Wang FZ. et al. Short-term effect of cardiac resynchronization therapy in patients with ischaemic or nonischaemic cardiomyopathy. Chin Med J. 2006;119(18):1507–10. [PubMed: 16996003]
61.
Kies P, Bax JJ, Molhoek SG. et al. Comparison of effectiveness of cardiac resynchronization therapy in patients with versus without diabetes mellitus. Am J Cardiol. 2005;96(1):108–11. [PubMed: 15979446]
62.
Kies P, Leclercq C, Bleeker GB. et al. Cardiac resynchronisation therapy in chronic atrial fibrillation: impact on left atrial size and reversal to sinus rhythm. Heart. 2006;92(4):490–4. [PMC free article: PMC1860874] [PubMed: 16159986]
63.
Koos R, Sinha AM, Markus K. et al. Comparison of left ventricular lead placement via the coronary venous approach versus lateral thoracotomy in patients receiving cardiac resynchronization therapy. Am J Cardiol. 2004;94(1):59–63. [PubMed: 15219510]
64.
Krahn AD, Snell L, Yee R. et al. Biventricular pacing improves quality of life and exercise tolerance in patients with heart failure and intraventricular conduction delay. Can J Cardiol. 2002;18(4):380–7. [PubMed: 11992131]
65.
Kuhlkamp V, InSync 7272 ICD World Wide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002;39(5):790–7. [PubMed: 11869843]
66.
Leclercq C, Victor F, Alonso C. et al. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation. Am J Cardiol. 2000;85(9):1154–6. [PubMed: 10781772]
67.
Leclercq C, Alonso C, Revault F. et al. Medium-term results of multisite biventricular stimulation in severe cardiac failure [in French] Arch Mal Coeur Vaiss. 2002b;95(4):253–9. [PubMed: 12055763]
68.
Lecoq G, Leclercq C, Leray E. et al. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. Eur Heart J. 2005;26(11):1094–100. [PubMed: 15728648]
69.
Lenom V, Materne P, Hoffer E. et al. Clinical value of cardiac resynchronization therapy in patients with congestive heart failure [in Fench] Rev Med Liege. 2005;60(2):101–8. [PubMed: 15819373]
70.
Leon AR, Abraham WT, Brozena S. et al. Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol. 2005;46(12):2298–304. [PubMed: 16360062]
71.
Lindner O, Vogt J, Kammeier A. et al. Effect of cardiac resynchronization therapy on global and regional oxygen consumption and myocardial blood flow in patients with non-ischaemic and ischaemic cardiomyopathy. Eur Heart J. 2005;26(1):70–6. [PubMed: 15615802]
72.
Macioce R, Cappelli F, Demarchi G. et al. Resynchronization of mitral valve annular segments reduces functional mitral regurgitation in cardiac resynchronization therapy. Minerva Cardioangiol. 2005;53(4):329–33. [PubMed: 16177677]
73.
Mair H, Sachweh J, Meuris B. et al. Surgical epicardial left ventricular lead versus coronary sinus lead placement in biventricular pacing. Eur J Cardiothorac Surg. 2005;27(2):235–42. [PubMed: 15691676]
74.
Mangiavacchi M, Gasparini M, Faletra F. et al. Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure. Am Heart J. 2006;151(2):477. e1-477.e6. [PubMed: 16442917]
75.
Marai I, Gurevitz O, Carasso S. et al. Improvement of congestive heart failure by upgrading of conventional to resynchronization pacemakers. Pacing Clin Electrophysiol. 2006;29(8):880–4. [PubMed: 16923005]
76.
Mascioli G, Curnis A, Bontempi L. et al. Biventricular pacing for patients with severe congestive heart failure: a single center experience. Ital Heart J. 2002;3(10):598–602. [PubMed: 12478818]
77.
Mele D, Pasanisi G, Capasso F. et al. Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. Eur Heart J. 2006;27(9):1070–8. [PubMed: 16574689]
78.
Molhoek SG, Bax JJ, van Erven L. et al. Effectiveness of resynchronization therapy in patients with end-stage heart failure. Am J Cardiol. 2002;90(4):379–83. [PubMed: 12161226]
79.
Molhoek SG, Bax JJ, Bleeker GB. et al. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol. 2004a;94(12):1506–9. [PubMed: 15589005]
80.
Molhoek SG, Bax JJ, van Erven L. et al. Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy. Am J Cardiol. 2004b;93(7):860–3. [PubMed: 15050489]
81.
Molhoek SG, van Erven L, Bootsma M. et al. QRS duration and shortening to predict clinical response to cardiac resynchronization therapy in patients with end-stage heart failure. Pacing Clin Electrophysiol. 2004c;27(3):308–13. [PubMed: 15009855]
82.
Molhoek SG, Bax JJ, Bleeker GB. et al. Long-term follow-up of cardiac resynchronization therapy in patients with end-stage heart failure. J Cardiovasc Electrophysiol. 2005;16(7):701–7. [PubMed: 16050826]
83.
Mortensen PT, Sogaard P, Mansour H. et al. Sequential biventricular pacing: evaluation of safety and efficacy. Pacing Clin Electrophysiol. 2004;27(3):339–45. [PubMed: 15009860]
84.
Murphy RT, Sigurdsson G, Mulamalla S. et al. Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy. Am J Cardiol. 2006;97(11):1615–21. [PubMed: 16728225]
85.
Nagele H, Schmidt E, Petersen B. et al. Experience with biventricular pacing in severe heart failure [in German] Herzschrittmacher. 2001;21(2):53–61.
86.
Navia JL, Atik FA, Grimm RA. et al. Minimally invasive left ventricular epicardial lead placement: surgical techniques for heart failure resynchronization therapy. Ann Thorac Surg. 2005;79(5):1536–44. [PubMed: 15854930]
87.
Niu HX, Hua W, Wang FZ. et al. Complications of cardiac resynchronization therapy in patients with congestive heart failure. Chin Med J. 2006;119(6):449–53. [PubMed: 16584641]
88.
Notabartolo D, Merlino JD, Smith AL. et al. Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy. Am J Cardiol. 2004;94(6):817–20. [PubMed: 15374800]
89.
O'Donnell D, Nadurata V, Hamer A. et al. Long-term variations in optimal programming of cardiac resynchronization therapy devices. Pacing Clin Electrophysiol. 2005;28(Suppl 1):S24–S26. [PubMed: 15683505]
90.
Oliva F, Frigerio M, Lunati M. et al. Benefits of Cardiac Resynchronization Therapy (CRT) in patients with advanced congestive heart failure listed for heart transplant [abstract]. Meeting and scientific sessions of the 25th anniversary meeting of the International Society for Heart and Lung Transplantation: 2005 Apr 25; Philadelphia, PA. J Heart Lung Transplant. 2005;24(2 Suppl):S84–S85.
91.
Ollitrault J, Ritter P, Mabo P. et al. Long-term experience with a preshaped left ventricular pacing lead. Pacing Clin Electrophysiol. 2003;26(1 Pt 2):185–8. [PubMed: 12687809]
92.
Pappone C, Vicedomini G, Augello G. et al. Combining electrical therapies for advanced heart failure: the Milan experience with biventricular pacing-defibrillation backup combination for primary prevention of sudden cardiac death. Am J Cardiol. 2003;91(9A):74F–80F. [PubMed: 12729853]
93.
Penicka M, Bartunek J, De Bruyne B. et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation. 2004;109(8):978–83. [PubMed: 14769701]
94.
Pitzalis MV, Iacoviello M, Romito R. et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol. 2005;45(1):65–9. [PubMed: 15629375]
95.
Porciani MC, Macioce R, Demarchi G. et al. Effects of cardiac resynchronization therapy on the mechanisms underlying functional mitral regurgitation in congestive heart failure. Eur J Echocardiog. 2006a;7(1):31–9. [PubMed: 16378918]
96.
Porciani MC, Valsecchi S, Demarchi G. et al. Evolution and prognostic significance of diastolic filling pattern in cardiac resynchronization therapy. Int J Cardiol. 2006b;112(3):322–8. [PubMed: 16318886]
97.
Puglisi A, Lunati M, Marullo AG. et al. Limited thoracotomy as a second choice alternative to transvenous implant for cardiac resynchronisation therapy delivery. Eur Heart J. 2004;25(12):1063–9. [PubMed: 15191778]
98.
Purnode P, Blommaert D, Eucher P. et al. Biventricular pacing and heart failure [in French] Louv Med. 2004;123(1):18–27.
99.
Reuter S, Garrigue S, Bordachar P. et al. Intermediate-term results of biventricular pacing in heart failure: correlation between clinical and hemodynamic data. Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1713–7. [PubMed: 11139907]
100.
Reuter S, Garrigue S, Barold SS. et al. Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. Am J Cardiol. 2002;89(3):346–50. [PubMed: 11809441]
101.
Ricci R, Pignalberi C, Ansalone G. et al. Early and late QRS morphology and width in biventricular pacing: relationship to lead site and electrical remodeling. J Interv Card Electrophysiol. 2002;6(3):279–85. [PubMed: 12154331]
102.
Ritter O, Koller ML, Fey B. et al. Progression of heart failure in right univentricular pacing compared to biventricular pacing. Int J Cardiol. 2006;110(3):359–65. [PubMed: 16297471]
103.
Rossillo A, Verma A, Saad EB. et al. Impact of coronary sinus lead position on biventricular pacing: mortality and echocardiographic evaluation during long-term follow-up. J Cardiovasc Electrophysiol. 2004;15(10):1120–5. [PubMed: 15485432]
104.
Salukhe TV, Francis DP, Clague JR. et al. Chronic heart failure patients with restrictive LV filling pattern have significantly less benefit from cardiac resynchronization therapy than patients with late LV filling pattern. Int J Cardiol. 2005;100(1):5–12. [PubMed: 15820279]
105.
Sawhney NS, Waggoner AD, Garhwal S. Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. Heart Rhythm. 2004;1(5):562–7. [PubMed: 15851220]
106.
Saxon LA, Greenfield RA, Crandall BG. et al. Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2006;17(5):520–5. [PubMed: 16684026]
107.
Sogaard P, Egeblad H, Kim WY. et al. Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol. 2002;40(4):723–30. [PubMed: 12204503]
108.
Stahlberg M, Braunschweig F, Gadler F. et al. Three year outcome of cardiac resynchronization therapy: a single center evaluation. Pacing Clin Electrophysiol. 2005;28(10):1013–7. [PubMed: 16221256]
109.
Taieb J, Moudni F, Benchaa T. et al. Resynchronization of the failing heart by pacing [in French] Ann Cardiol Angeiol (Paris) 2002;51(5):289–95. [PubMed: 12515106]
110.
Tedrow UB, Kramer DB, Stevenson LW. et al. Relation of Right Ventricular Peak Systolic Pressure to Major Adverse Events in Patients Undergoing Cardiac Resynchronization Therapy. Am J Cardiol. 2006;97(12):1737–40. [PubMed: 16765124]
111.
Teo WS, Kam R, Hsu LF. Treatment of heart failure - role of biventricular pacing for heart failure not responding well to drug therapy. Singapore Med J. 2003;44(3):114–22. [PubMed: 12953723]
112.
Theuns DA, Thornton AS, Klootwijk AP. et al. Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: differences between primary and secondary prophylaxis. Eur J Heart Fail. 2005;17(6):1027–32. [PubMed: 16109500]
113.
Toussaint JF, Lavergne T, Kerrou K. et al. Basal asynchrony and resynchronization with biventricular pacing predict long-term improvement of LV function in heart failure patients. Pacing Clin Electrophysiol. 2003;26(9):1815–23. [PubMed: 12930495]
114.
Vidal B, Sitges M, Marigliano A. et al. Relation of response to cardiac resynchronization therapy to left ventricular reverse remodeling. Am J Cardiol. 2006;97(6):876–81. [PubMed: 16516593]
115.
Waggoner AD, Rovner A, de las Fuentes L. et al. Clinical outcomes after cardiac resynchronization therapy: importance of left ventricular diastolic function and origin of heart failure. J Am Soc Echocard. 2006;19(3):307–13. [PubMed: 16500494]
116.
Witte KKA, Pipes RR, Nanthakumar K. et al. Biventricular Pacemaker Upgrade in Previously Paced Heart Failure Patients-Improvements in Ventricular Dyssynchrony. J Card Fail. 2006;12(3):199–204. [PubMed: 16624685]
117.
Ypenburg C, van Erven L, Bleeker GB. et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. J Am Coll Cardiol. 2006;48(3):464–70. [PubMed: 16875970]
118.
Yu CM, Chau E, Sanderson JE. et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002a;105(4):438–45. [PubMed: 11815425]
119.
Yu CM, Fung WH, Lin H. et al. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2002b;91(6):684–8. [PubMed: 12633798]
120.
Yu CM, Fung JW, Chan CK. et al. Comparison of efficacy of reverse remodeling and clinical improvement for relatively narrow and wide QRS complexes after cardiac resynchronization therapy for heart failure. J Cardiovasc Electrophysiol. 2004;15(9):1058–65. [PubMed: 15363081]
121.
Yu CM, Bleeker GB, Fung JW. et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112(11):1580–6. [PubMed: 16144994]
122.
Zhang Q, Fung J-H, Auricchio A. et al. Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure. Eur Heart J. 2006;27(12):1423–30. [PubMed: 16682380]
123.
Chugh A, Scharf C, Hall B. et al. Prevalence and management of inappropriate detection and therapies in patients with first-generation biventricular pacemaker-defibrillators. Pacing Clin Electrophysiol. 2005;28(1):44–50. [PubMed: 15660802]
124.
de Cock CC, van Campen CM, Visser CA. Major dissection of the coronary sinus and its tributaries during lead implantation for biventricular stimulation: angiographic followup. Europace. 2004;6(1):43–7. [PubMed: 14697725]
125.
De Martino G, Sanna T, Dello Russo A. et al. A randomized comparison of alternative techniques to achieve coronary sinus cannulation during biventricular implantation procedures. J Interv Card Electrophysiol. 2004;10(3):227–30. [PubMed: 15133359]
126.
De Martino G, Messano L, Santamaria M. et al. A randomized evaluation of different approaches to coronary sinus venography during biventricular pacemaker implants. Europace. 2005;7(1):73–6. [PubMed: 15670971]
127.
Gasparini M, Galimberti P, Regoli F. et al. Delayed defibrillation testing in patients implanted with biventricular ICD (CRT-D): a reliable and safe approach. J Cardiovasc Electrophysiol. 2005;16(12):1279–83. [PubMed: 16403056]
128.
Kautzner J, Riedlbauchova L, Cihak R. et al. Technical aspects of implantation of LV lead for cardiac resynchronization therapy in chronic heart failure. Pacing Clin Electrophysiol. 2004;27(6 Pt 1):783–90. [PubMed: 15189535]
129.
Lewicka-Nowak E, Sterlinski M, Dabrowska-Kugacka A. et al. Complications of permanent biventricular pacing in patients with advanced heart failure [in Polish] Folia Cardiol. 2005;12(5):343–53.
130.
Purerfellner H, Nesser HJ, Winter S. et al. Transvenous left ventricular lead implantation with the EASYTRAK lead system: the European experience. Am J Cardiol. 2000;86(9A):157K–64K. [PubMed: 11084117]
131.
Romeyer-Bouchard C, Da Costa A, Abdellaoui L. et al. Simplified cardiac resynchronization implantation technique involving right access and a triple-guide/single introducer approach. Heart Rhythm. 2005;2(7):714–9. [PubMed: 15992727]
132.
Schuchert A, Seidl K, Pfeiffer D. et al. Two-year performance of a preshaped lead for left ventricular stimulation. Pacing Clin Electrophysiol. 2004;27(12):1610–4. [PubMed: 15613123]
133.
Moss AJ, Hall WJ, Cannom DS. et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40. [PubMed: 8960472]
134.
Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337(22):1569–75. [PubMed: 9371853]
135.
Moss AJ, Zareba W, Hall WJ. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. [PubMed: 11907286]
136.
Bansch D, Antz M, Boczor S. et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT) Circulation. 2002;105(12):1453–8. [PubMed: 11914254]
137.
Strickberger SA, Hummel JD, Bartlett TG. et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707–12. [PubMed: 12767651]
138.
Kadish A, Dyer A, Daubert JP. et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8. [PubMed: 15152060]
139.
Hohnloser SH, Kuck KH, Dorian P. et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8. [PubMed: 15590950]
140.
Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. [PubMed: 15659722]
141.
AVID investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337(22):1576–83. [PubMed: 9411221]
142.
Connolly SJ, Gent M, Roberts RS. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302. [PubMed: 10725290]
143.
Kuck KH, Cappato R, Siebels J. et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH) Circulation. 2000;102(7):748–54. [PubMed: 10942742]
144.
Alter P, Waldhans S, Plachta E. et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28(9):926–32. [PubMed: 16176531]
145.
Backenkohler U, Erdogan A, Steen-Mueller MK. et al. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest. J Cardiovasc Electrophysiol. 2005;16(5):478–82. [PubMed: 15877617]
146.
Blangy H, Sadoul N, de Chillou C. et al. Characteristics and causes of death in 283 patients with implanted defibrillators {in French] Arch Mal Coeur Vaiss. 2003;96(1):7–14. [PubMed: 12613144]
147.
Bode-Schnurbus L, Bocker D, Block M. et al. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart. 2003;89(10):1157–62. [PMC free article: PMC1767911] [PubMed: 12975406]
148.
Bokhari F, Newman D, Greene M. et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS) Circulation. 2004;110(2):112–6. [PubMed: 15238454]
149.
Bruch C, Gotzmann M, Sindermann J. et al. Prognostic value of a restrictive mitral filling pattern in patients with systolic heart failure and an implantable cardioverter-defibrillator. Am J Cardiol. 2006;97(5):676–80. [PubMed: 16490436]
150.
Brunckhorst C, Binggeli C, Hellermann JP. et al. ICD therapy in patients with coronary artery disease—incidence of adequate interventions [in Germn] Ther Umsch. 2004;61(4):271–8. [PubMed: 15139319]
151.
Buxton AE, Lee KL, Fisher JD. et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90. [PubMed: 10601507]
152.
Capoferri M, Schwick N, Tanner H. et al. Incidence of arrhythmic events in patients with implantable cardioverter-defibrillator for primary and secondary prevention of sudden cardiac death. Swiss Med Wkly. 2004;134(1112):154–8. [PubMed: 15106019]
153.
Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in highrisk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol. 2005;45(9):1474–81. [PubMed: 15862422]
154.
Chan PS, Chow T, Kereiakes D. et al. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med. 2006;166(20):2228–33. [PubMed: 17101941]
155.
Cuesta A, Mont L, Rogel U. et al. Comparison of effectiveness of implantable cardioverter defibrillator in patients with idiopathic dilated cardiomyopathy versus those with proved coronary heart disease. Am J Cardiol. 2003;92(10):1227–30. [PubMed: 14609607]
156.
Dorian P, Philippon F, Thibault B. et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 2004b;1(5):540–7. [PubMed: 15851216]
157.
Dubner S, Valero E, Pesce R. et al. A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study. Ann Noninvasive Electrocardiol. 2005;10(4):420–8. [PubMed: 16255752]
158.
Duray G, Richter S, Manegold J. et al. Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. J Interv Card Electrophysiol. 2005;14(3):169–73. [PubMed: 16421693]
159.
Elhendy A, Chapman S, Porter TR. et al. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol. 2005;46(9):1721–6. [PubMed: 16256875]
160.
Ellenbogen KA, Wood MA, Shepard RK. et al. Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. J Am Coll Cardiol. 2003;41(1):73–80. [PubMed: 12570948]
161.
Ermis C, Zadeii G, Zhu AX. et al. Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy: role of beta-blocker or amiodarone treatment. J Cardiovasc Electrophysiol. 2003;14(6):578–83. [PubMed: 12875416]
162.
Evonich RF, Maheshwari A, Gardiner JC. et al. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia. J Interv Card Electrophysiol. 2004;11(1):59–65. [PubMed: 15273456]
163.
Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T. et al. Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy. Europace. 2005;7(2):184–92. [PubMed: 15763536]
164.
Greenberg D, Katz A, Epstein M. et al. Implantable cardioverter defibrillators in Israel: utilization and implantation trends. Int J Cardiol. 2002;82(1):17–23. [PubMed: 11786153]
165.
Grimm W, Hoffman JJ, Muller HH. et al. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30% J Am Coll Cardiol. 2002;39(5):780–7. [PubMed: 11869841]
166.
Ho AT, Pai SM, Timothy P. et al. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2005;28(7):647–53. [PubMed: 16008799]
167.
Koplan BA, Epstein LM, Albert CM. et al. Survival in octogenarians receiving implantable defibrillators. Am Heart J. 2006;152(4):714–9. [PubMed: 16996846]
168.
Lampert R, McPherson CA, Clancy JF. et al. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. J Am Coll Cardiol. 2004;43(12):2293–9. [PubMed: 15193696]
169.
Leosdottir M, Reimarsdottir G, Gottskalksson G. et al. The use of implantable cardioverter defibrillators in Iceland: a retrospective population based study. BMC Cardiovascasc Disorders. 2006;6:22. [PMC free article: PMC1481553] [PubMed: 16723025]
170.
Nazarian S, Maisel WH, Miles JS. et al. Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure. Am Heart J. 2005;150(5):955–60. [PubMed: 16290971]
171.
Noseworthy PA, Lashevsky I, Dorian P. et al. Feasibility of implantable cardioverter defibrillator use in elderly patients: a case series of octogenarians. Pacing Clin Electrophysiol. 2004;27(3):373–8. [PubMed: 15009867]
172.
Parkash R, Stevenson WG, Epstein LM. et al. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J. 2006;151(2):397–403. [PubMed: 16442906]
173.
Pires LA, Sethuraman B, Guduguntla VD. et al. Outcome of women versus men with ventricular tachyarrhythmias treated with the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol. 2002;13(6):563–8. [PubMed: 12108497]
174.
Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? J Cardiovasc Electrophysiol. 2006;17(2):140–5. [PubMed: 16533250]
175.
Raitt MH, Connor WE, Morris C. et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293(23):2884–91. [PubMed: 15956633]
176.
Raviele A, Bongiorni MG, Brignole M. et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial. Europace. 2005;7(4):327–37. [PubMed: 16028343]
177.
Robin J, Weinberg K, Tiongson J. et al. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. Heart Rhythm. 2006;3(10):1196–201. [PubMed: 17018351]
178.
Russo AM, Nayak H, Verdino R. et al. Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified? Pacing Clin Electrophysiol. 2003;26(12):2289–95. [PubMed: 14675014]
179.
Saba S, Atiga WL, Barrington W. et al. Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. J Heart Lung Transplant. 2003;22(4):411–8. [PubMed: 12681418]
180.
Sanchez JM, Katsiyiannis WT, Gage BF. et al. Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm. 2005;2(4):367–73. discussion 374–375. [PubMed: 15851337]
181.
Sanchez JM, Greenberg SL, Chen J. et al. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Heart Rhythm. 2006;3(4):443–9. [PubMed: 16567292]
182.
Schaer BA, Ammann P, Sticherling C. et al. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function. Int J Cardiol. 2006;108(1):26–30. [PubMed: 16516695]
183.
Sears SF, Serber ER, Lewis TS. et al. Do positive health expectations and optimism relate to quality-of-life outcomes for the patient with an implantable cardioverter defibrillator? J Cardiopulm Rehabil. 2004;24(5):324–31. [PubMed: 15602153]
184.
Takahashi T, Bhandari AK, Watanuki M. et al. High incidence of device-related and lead-related complications in the dual-chamber implantable cardioverter defibrillator compared with the single-chamber version. Circulation J. 2002;66(8):746–50. [PubMed: 12197599]
185.
Tandri H, Griffith LS, Tang T. et al. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm. 2006;3(7):762–8. [PubMed: 16818202]
186.
Telfer EA, Mecca A, Martini M. et al. Implantable defibrillator use for de novo ventricular tachyarrhythmias encountered after cardiac surgery. Pacing Clin Electrophysiol. 2002;25(6):951–6. [PubMed: 12137348]
187.
Theuns DA, Szili-Torok T, Jordaens LJ. Defibrillation efficacy testing: long-term follow-up and mortality. Europace. 2005b;7(6):509–15. [PubMed: 16216750]
188.
Trappe HJ. Biventricular pacing therapy in patients with congestive heart failure and ventricular tachyarrhythmias [abstract]. Jahrestagung: Deutschen Gesellschaft fur Biomedizinische Technik: 2002 Sept; Karlsurhe, Germany. Dtsch Ges Biomed Tech 2002;243–9.
189.
Wase A, Basit A, Nazir R. et al. Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysiol. 2004;11(3):199–204. [PubMed: 15548886]
190.
Wilkoff BL, Ousdigian KT, Sterns LD. et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48(2):330–9. [PubMed: 16843184]
191.
Zecchin M, Di Lenarda A, Proclemer A. et al. The role of implantable cardioverter defibrillator for primary vs. secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy. [erratum appears in Europace. 2005 Jan;7(1):91] Europace. 2004;6(5):400–6. [PubMed: 15294264]
192.
Carlsson J, Schulte B, Erdogan A. et al. Prospective randomized comparison of two defibrillation safety margins in unipolar, active pectoral defibrillator therapy. Pacing Clin Electrophysiol. 2003;26(2 Pt 1):613–8. [PubMed: 12710322]
193.
Dorian P, Borggrefe M, Al-Khalidi HR. et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004a;110(24):3646–54. [PubMed: 15533855]
194.
Friedman PA, McClelland RL, Bamlet WR. et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006;113(25):2871–9. [PubMed: 16769912]
195.
Grimm W, Plachta E, Maisch B. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy. Pacing Clin Electrophysiol. 2006;29(7):759–64. [PubMed: 16884513]
196.
Hreybe H, Ezzeddine R, Barrington W. et al. Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks. Am J Cardiol. 2006;97(4):544–6. [PubMed: 16461053]
197.
Lickfett L, Bitzen A, Arepally A. et al. Incidence of venous obstruction following insertion of an implantable cardioverter defibrillator. A study of systematic contrast venography on patients presenting for their first elective ICD generator replacement. Europace. 2004;6(1):25–31. [PubMed: 14697723]
198.
Niehaus M, de Sousa M, Klein G. et al. Chronic experiences with a single lead dual chamber implantable cardioverter defibrillator system. Pacing Clin Electrophysiol. 2003;26(10):1937–43. [PubMed: 14516332]
199.
Saeed M, Jin A, Pontone G. et al. Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003;8(3):219–26. [PubMed: 14510657]
200.
Theuns DA, Klootwijk AP, Goedhart DM. et al. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol. 2004;44(12):2362–7. [PubMed: 15607399]
201.
Theuns DA, Klootwijk AP, Simoons ML. et al. Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. Am J Cardiol. 2005a;95(2):271–4. [PubMed: 15642568]
202.
Tiroke A, Ganeeva ON, Syrkin AL. Unmotivated malfunction of implanted cardioverter-defibrillator and ways of its correction [in Russian] Klin Med (Mosk) 2003;81(5):26–30. [PubMed: 12856564]
203.
Reynolds MR, Cohen DJ, Kugelmass AD. et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47(12):2493–7. [PMC free article: PMC1800827] [PubMed: 16781379]
204.
Al-Khatib SM, Lucas FL, Jollis JG. et al. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol. 2005;46(8):1536–50. [PubMed: 16226180]
205.
Bansch D, Steffgen F, Gronefeld G. et al. The 1 + 1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 2004;110:1022–9. [PubMed: 15326069]
206.
Boriani G, Wollmann C, Biffi M. et al. Evaluation of a dual chamber implantable cardioverter defibrillator for the treatment of atrial and ventricular arrhythmias. Pace. 2003;26(Pt. II):461–5. [PubMed: 12687868]
207.
Brockes C, Rahn-Schonbeck M, Duru F. et al. ICD implantation with and without combined myocardial revascularisation - incidence of ICD therapy and late survival. Thorac Cardiovasc Surg. 2002;50:333–6. [PubMed: 12457308]
208.
Gradaus R, Block M, Brachmann J. et al. Mortality, morbidity, and complications in 3,344 patients with implantable cardioverter defibrillators: results from the German ICD Registry EURID. Pace. 2003;26:1511–8. [PubMed: 12914630]
209.
Hlatky MA, Saynina O, McDonald KM. et al. Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. Am Heart J. 2002;144:397–403. [PubMed: 12228775]
210.
Nademanee K, Veerakul G, Mower M. et al. Defibrillator versus B-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221–6. [PubMed: 12695290]
211.
Rosenqvist M, Beyer T, Block M. et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. Circulation. 1998;98:663–70. [PubMed: 9715859]
212.
Schlapfer J, Rapp F, Kappenberger L. et al. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. J Am Coll Cardiol. 2002;39:1813–9. [PubMed: 12039497]
213.
Vollmann D, Ahern T, Gerritse B. et al. Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing. Am Heart J. 2003;146:1066–70. [PubMed: 14661000]
214.
Wiegand UKH, LeJeune D, Boguschewski F. et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest. 2004;126:1177–86. [PubMed: 15486380]
215.
Kindermann M, Hennen B, Jung J. et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE) J Am Coll Cardiol. 2006;47(10):1927–37. [PubMed: 16697307]
216.
Woo GW, Petersen-Stejskal S, Johnson JW. et al. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol. 2005;12(2):107–13. [PubMed: 15744462]
217.
Stevenson LW. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? Circulation. 2006;114(2):101–3. [PubMed: 16831996]
218.
Cleland JGF, Daubert JC, Erdmann E. et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase] Eur Heart J. 2006;27(16):1928–32. [PubMed: 16782715]
219.
Flather MD, Yusuf S, Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575–81. [PubMed: 10821360]
220.
Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134(7):550–60. [PubMed: 11281737]
221.
Pitt B, Zannad F, Remme WJ. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. [PubMed: 10471456]
222.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75. [PubMed: 11759645]
223.
Hjalmarson A, Goldstein S, Fagerberg B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295–302. [PubMed: 10714728]
224.
Ellenbogen KA, Hellkamp AS, Wilkoff BL. et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J Cardiol. 2003;92(6):740–1. [PubMed: 12972124]
225.
Medina-Ravell VA, Lankipalli RS, Yan GX. et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation. 2003;107(5):740–6. [PubMed: 12578878]
226.
Mehra MR, Greenberg BH. Cardiac resynchronization therapy: caveat medicus! J Am Coll Cardiol. 2004;43(7):1145–8. [PubMed: 15063420]
227.
Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. Curr Opin Cardiol. 2006;21(1):20–6. [PubMed: 16355025]
228.
Yu CM, Abraham WT, Bax J. et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design. Am Heart J. 2005;149(4):600–5. [PubMed: 15990740]
229.
Kass DA. Predicting cardiac resynchronization response by QRS duration: the long and short of it. J Am Coll Cardiol. 2003;42(12):2125–7. [PubMed: 14680738]
230.
Moss AJ. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation. 2005;111(19):2537–49. discussion 2537–2549. [PubMed: 15900623]
231.
Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation. 2005;111(19):2537–49. discussion 2537–2549. [PubMed: 15897357]
232.
Moss AJ, Greenberg H, Case RB. et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760–5. [PubMed: 15583079]
233.
Huikuri HV, Castellanos A, Myerberg RJ. Sudden death due to cardiac arryhythmias. N Engl J Med. 2001;345:1473–82. [PubMed: 11794197]
234.
Hammill S, Phurrough S, Brindis R. The National ICD Registry: now and into the future. Heart Rhythm. 2006;3(4):470–3. [PubMed: 16567298]
235.
Myerburg RJ, Castellanos A. Clinical research designs and implantable defibrillator indications: spend in the beginning or pay at the end. J Am Coll Cardiol. 2006;47(1):108–11. [PubMed: 16386672]
236.
De Lurgio DB, Foster E, Higginbotham MB. et al. A comparison of cardiac resynchronization by sequential biventricular pacing and left ventricular pacing to simultaneous biventricular pacing: rationale and design of the DECREASE-HF clinical trial. J Card Fail. 2005;11:233–9. [PubMed: 15812753]
237.
Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics-2007 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;[Epub ahead of print]. Available at http://circ.ahajournals.org/cgi/reprint/CIRCUL ATIONAHA.106.179918v1. (Accessed 19 December 2006)
238.
Cowie MR, Mosterd A, Wood DA. The epidemiology of heart failure. Eur Heart J. 1997;18(2):208–825. [PubMed: 9043837]
239.
Redfield MM, Jacobsen SJ, Burnett JC Jr. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202. [PubMed: 12517230]
240.
Heart and Stroke Foundation Canada. The changing face of heart disease and stroke in Canada. Ottawa, ON: Heart and Stroke Foundation Canada; 2000.
241.
Lloyd-Jones DM, Wang TJ, Leip EP. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. [PubMed: 12473553]
242.
MacIntyre K, Capewell S, Stewart S. et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation. 2000;102(10):1126–31. [PubMed: 10973841]
243.
Hunt SA, Abraham WT, Chin MH. et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235. [PubMed: 16160202]
244.
Arnold JM, Liu P, Demers C. et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22(1):23–45. [PMC free article: PMC2538984] [PubMed: 16450016]
245.
Jong P, Vowinckel E, Liu PP. et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162(15):1689–94. [PubMed: 12153371]
246.
Poole-Wilson PA, Uretsky BF, Thygesen K. et al. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;89(1):42–8. [PMC free article: PMC1767481] [PubMed: 12482789]
247.
Massie BM. Fifteen years of heart-failure trials: what have we learned? Lancet. 1998;352(Suppl 1):SI29–33. [PubMed: 9736477]
248.
McAlister FA, Ezekowitz JA, Wiebe N. et al. Cardiac resynchronization therapy in patients with symptomatic heart failure: a systematic review. Ann Intern Med. 2004;141(5):381–90. [PubMed: 15353430]
249.
Hartling L, McAlister F, Rowe BH. et al. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med. 2005;142(12 Pt 2):1100–11. [PubMed: 15968035]
250.
Ezekowitz J, Armstrong PW, McAlister F. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med. 2003;138(6):445–52. [PubMed: 12639076]
251.
Mond HG, Irwin M, Morillo C. et al. The world survey of cardiac pacing and cardioverter defibrillators: calendar year 2001. Pacing Clin Electrophysiol. 2004;27(7):955–64. [PubMed: 15271016]
252.
Schulz KF, Chalmers I, Hayes RJ. et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–12. [PubMed: 7823387]
253.
Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
254.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84. [PMC free article: PMC1756728] [PubMed: 9764259]
255.
Follmann D, Elliott P, Suh I. et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45(7):769–73. [PubMed: 1619456]
256.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
257.
Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med. 2002;21(15):2131–44. [PubMed: 12210629]
258.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed: 7786990]
259.
Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
260.
Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. JAMA. 2000;95(449):89–98.
261.
Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, 1985.
262.
Gregoratos G, Cheitlin MD, Conill A. et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation) Circulation. 1998;97(13):1325–35. [PubMed: 9570207]
263.
Berenbom LD, Weiford BC, Vacek JL. et al. Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II. Ann Noninvasive Electrocardiol. 2005;10(4):429–35. [PubMed: 16255753]
264.
Gasparini M, Lunati M, Bocchiardo M. et al. Cardiac resynchronization and implantable cardioverter defibrillator therapy: preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry. Pacing Clin Electrophysiol. 2003b;26(1 Pt 2):148–51. [PubMed: 12687801]
265.
Olsson LG, Swedberg K, Clark AL. et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J. 2005;26(8):778–93. [PubMed: 15774495]
266.
Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Content, reliability and validity of a new measure—the Minnesota living with heart failure questionnaire. Heart Failure. 1987;3:198–208.
267.
Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124(4):1017–25. [PubMed: 1529875]
268.
Rector TS, Johnson G, Dunkman WB. et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI71–VI77. [PubMed: 8500243]
269.
Lindenfeld J, Feldman AM, Saxon L. et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007;115(2):204–12. [PubMed: 17190867]
270.
Kuhlkamp V. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol. 2002;39(5):790–7. [PubMed: 11869843]
271.
Bleeker GB, Bax JJ, Fung JW. et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97(2):260–3. [PubMed: 16442375]
272.
Gold MR, Auricchio A, Hummel JD. et al. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005;2(4):376–81. [PubMed: 15851339]
273.
Gasparini M, Mantica M, Galimberti P. et al. Is the outcome of cardiac resynchronization therapy related to the underlying etiology? Pacing Clin Electrophysiol. 2003;26(1 Pt 2):175–80. [PubMed: 12687807]
274.
Breithardt OA, Stellbrink C, Kramer AP. et al. Echocardiographic quantification of left ventricular asynchrony predicts an acute hemodynamic benefit of cardiac resynchronization therapy. J Am Coll Cardiol. 2002;40(3):536–45. [PubMed: 12142123]
275.
Bleeker GB, Schalij MJ, Molhoek SG. et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol. 2004;15(5):544–9. [PubMed: 15149423]
276.
Ghio S, Constantin C, Klersy C. et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J. 2004;25(7):571–8. [PubMed: 15120054]
277.
Yu CM, Yang H, Lau CP. et al. Regional left ventricle mechanical asynchrony in patients with heart disease and normal QRS duration: implication for biventricular pacing therapy. Pacing Clin Electrophysiol. 2003;26(2 Pt 1):562–70. [PubMed: 12710315]
278.
Turner MS, Bleasdale RA, Vinereanu D. et al. Electrical and mechanical components of dyssynchrony in heart failure patients with normal QRS duration and left bundle-branch block: impact of left and biventricular pacing. Circulation. 2004;109(21):2544–9. [PubMed: 15148267]
279.
Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet. 2003;362(9378):147–58. [PubMed: 12867118]
280.
McAlister F, Tu JV, Newman A. et al. How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. Eur Heart J. 2006;27(3):323–9. [PubMed: 16105850]
281.
Cleland JG, Swedberg K, Follath F. et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442–63. [PubMed: 12633546]
282.
Pires LA, Sethuraman B, Guduguntla VD. et al. Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med. 1999;107(6):549–55. [PubMed: 10625022]
283.
Curtis AB, Abraham WT, Chen PS. et al. Highlights of Heart Rhythm 2004, the Annual Scientific Sessions of the Heart Rhythm Society; 2004 May 19–22; San Francisco, CA. J Am Coll Cardiol. 2004;44(8):1550–6. [PubMed: 15489084]
284.
Fantoni C, Kawabata M, Massaro R. et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol. 2005;16(2):112–9. discussion 120–121. [PubMed: 15720446]
285.
Pablos Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222–5. [PubMed: 9438743]
286.
Uretsky BF, Thygesen K, Armstrong PW. et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102(6):611–6. [PubMed: 10931799]
287.
Nichol G, Kaul P, Huszti E. et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141(5):343–51. [PubMed: 15353425]
288.
Feldman AM, de Lissovoy G, Bristow MR. et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46(12):2311–21. [PubMed: 16360064]
289.
Calvert MJ, Freemantle N, Yao G. et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26(24):2681–8. [PubMed: 16284203]
290.
Fox M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cardiac resynchronization (biventricular pacing) for heart failure: a systematic review and economic model [Web Page]. 7 September 2006; Available at http://www​.nice.org.uk/page​.aspx?o=388638. (Accessed 28 September 2006).
291.
Hlatky MA. Cost effectiveness of cardiac resynchronization therapy. J Am Coll Cardiol. 2005;46(12):2322–4. [PubMed: 16360065]
292.
Shen AY, Wang X, Doris J. et al. Proportion of patients in a congestive heart failure care management program meeting criteria for cardiac resynchronization therapy. Am J Cardiol. 2004;94(5):673–6. [PubMed: 15342309]
293.
Grimm W, Sharkova J, Funck R. et al. How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy? Pacing Clin Electrophysiol. 2003;26(1 Pt 2):155–7. [PubMed: 12687803]
294.
Pedone C, Grigioni F, Boriani G. et al. Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. Am J Cardiol. 2004;93(3):371–3. [PubMed: 14759396]
295.
Toma M, McAlister F, Ezekowitz J. et al. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. Am J Cardiol. 2006;97(6):882–5. [PubMed: 16516594]
296.
Bennett JA, Riegel B, Bittner V. et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262–70. [PubMed: 12122390]
297.
Goldenberg I, Moss AJ, Hall WJ. et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation. 2006;113(24):2810–7. [PubMed: 16769917]
298.
Zipes DP, Camm AJ, Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J Am Coll Cardiol. 2006;48(5):e247–346. [PubMed: 16949478]
299.
Irvine J, Dorian P, Baker B. et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS) Am Heart J. 2002;144:282–9. [PubMed: 12177646]
300.
Sears SF Jr, Todaro JF, Lewis TS. et al. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22(7):481–9. [PubMed: 10410293]
301.
Carroll DL, Hamilton G. Quality of life in implanted cardioverter defibrillator recipients: the impact of a device shock. Heart Lung. 2005;34(3):169–78. [PubMed: 16015221]
302.
Sneed NV, Finch NJ, Leman RB. The impact of device recall on patients and family members of patients with automatic implantable cardioverter defibrillators. Heart Lung. 1994;23(4):317–22. [PubMed: 7960857]
303.
Maisel WH, Sweeney MO, Stevenson WG. et al. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA. 2001;286(7):793–9. [PubMed: 11497532]
304.
Maisel WH. Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions. JAMA. 2005;294(8):955–8. [PubMed: 16118386]
305.
Goldenberg I, Moss AJ, McNitt S. et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(9):1811–7. [PubMed: 16682305]
306.
Costantini O. The Alternans Before Cardioverter Defibrillator (ABCD) trial: a non-invasive strategy for primary prevention of sudden cardiac death using T wave alternans. American Heart Association 2006 Sceientific Sessions; Late Breaking Clinical Trials III; 2006 Nov 15; Chicago, IL. [Web Page]. Available at http://www​.medscape.com​/viewarticle/547941. (Accessed 27 December 2006).
307.
Chan PS, Stein K, Chow T. et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48(1):112–21. [PubMed: 16814657]
308.
Wathen MS, DeGroot PJ, Sweeney MO. et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110(17):2591–6. [PubMed: 15492306]
309.
Auricchio A, Sommariva L, Salo RW. et al. Improvement of cardiac function in patients with severe congestive heart failure and coronary artery disease by dual chamber pacing with shortened AV delay. Pacing Clin Electrophysiol. 1993;16(10):2034–43. [PubMed: 7694250]
310.
Kuhlkamp V, Dornberger V, Mewis C. et al. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol. 1999;10(7):905–15. [PubMed: 10413370]
311.
Deisenhofer I, Kolb C, Ndrepepa G. et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol. 2001;12(2):134–42. [PubMed: 11232608]
312.
Saad EB, Marrouche NF, Martin DO. et al. Frequency and associations of symptomatic deterioration after dual-chamber defibrillator implantation in patients with ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;90(1):79–82. [PubMed: 12088790]
313.
Wilkoff BL, Cook JR, Epstein AE. et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. N Engl J Med. 2002;288(24):3115–23. [PubMed: 12495391]
314.
Hughes S. DATAS restores confidence in dual-chamber ICDs. July 21, 2006. theheart.org. [HeartWire>News][database on the Internet]. Montreal (QC): WebMD; c1999-2006 [cited 2006 Sept 26]. Available from: http://www​.theheart.org/article/725387​.do.
315.
Gregoratos G, Abrams J, Epstein AE. et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) Circulation. 2002;106(16):2145–61. [PubMed: 12379588]
316.
Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol. 2005;45:2022–5. [PubMed: 15963404]
317.
Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471–80. [PubMed: 16207849]
318.
Mark DB, Nelson CL, Anstrom KJ. et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation. 2006;114(2):135–42. [PubMed: 16818817]
319.
Zwanziger J, Hall WJ, Dick AW. et al. The cost-effectiveness of implantable cardioverter-defibrillators. Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) J Am Coll Cardiol. 2006;47:2310–8. [PubMed: 16750701]
320.
Al-Khatib SM, Anstrom KJ, Eisenstein EL. et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593–600. [PubMed: 15838065]
321.
Linde C, Gold M, Abraham WT. et al. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J. 2006;151:288–94. [PubMed: 16442890]
322.
Moss AJ, Brown MW, Cannom DS. et al. Multicenter automatic defibrillator implantation trial—cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol. 2005;19(Suppl 4):34–43. [PubMed: 16274414]
323.
Teuteberg JJ, Lewis EF, Nohria A. et al. Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. J Cardiac Failure. 2006;12:47–53. [PubMed: 16500580]
324.
Daubert JC, Leclercq C, Mabo P. There is plenty of room for cardiac resynchronization therapy devices without back-up defibrillators in the electrical treatment of heart failure. J Am Coll Cardiol. 2005;46:2204–7. [PubMed: 16360047]
Bookshelf ID: NBK38305

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...